Advancements in IDH-Mutated Grade 2 Glioma Treatment: Maximal Resection and Role of Vorasidenib

Over the past two decades, significant progress has been made in the treatment of IDH-mutated grade 2 gliomas, particularly with key findings from randomized trials. Adding chemotherapy (procarbazine, CCNU, vincristine) to radiation therapy has been shown to significantly improve long-term survival, with a notable survival advantage (13.3 years versus 7.8 years). Additionally, the use of vorasidenib, a new well-tolerated drug targeting IDH mutations, has demonstrated improved short-term progression-free survival compared to a placebo. Moreover, numerous large retrospective studies have highlighted the major benefit of maximal resection in improving patient outcomes. However, several critical questions remain unanswered, such as the advantages of supra-total resections and the optimal timing for adjuvant treatment.

In this context, a new study published in The Lancet Regional Health—Europe by Ng et al. analyzed a retrospective series of 600 IDH-mutated glioma patients. The study found that supratotal resections were associated with better survival compared to total resections, and total resections provided better survival outcomes than partial resections. Importantly, the functional status of patients remained mostly unaffected by the surgery, underscoring the importance of extensive resection for both survival and cognitive outcomes.

Ng et al.’s findings highlight the power of large, retrospective series with advanced methodologies, such as propensity scores, in evaluating treatment effects over extended periods. This comprehensive approach provides more robust data compared to randomized trials with short follow-up periods. Their study also demonstrates the importance of awake neuropsychological monitoring during resections, which helps preserve cognitive function while improving survival. This long-term, holistic approach should become the new standard in IDH-mutated glioma clinical research.

Benefits of Supratotal Resections in Glioma Treatment

Ng et al.’s study offers the most convincing analysis to date of the benefits of supratotal versus total resections in IDH-mutated grade 2 gliomas. As the rate of incidental detection of small tumors increases due to enhanced access to magnetic resonance imaging (MRI), the likelihood of achieving supratotal resections will rise in the coming years. In high-risk patients, such as those with astrocytomas and significant postoperative residual tumor (greater than 15 cc), the long-term adverse effects of early radiation therapy are less concerning. These patients could benefit from upfront postoperative chemoradiotherapy, especially if tumor growth exceeds 8 mm per year.

The study also highlights the importance of organizing the care of IDH-mutated glioma patients in specialized neurosurgical and neuro-oncological centers. Given the rarity of these tumors and the expertise required for awake surgery, it is crucial for such centers to have a multidisciplinary team, including neuropsychologists, speech therapists, and rehabilitation specialists, to ensure the best outcomes.

Enhancing Functional Outcomes and Reducing Fatigue

Although Ng et al.’s study demonstrates impressive survival and cognitive outcomes, there is still room for improvement in functional recovery, particularly in areas such as executive functions. New machine-learning techniques are being developed to determine the optimal level of resection that will maximize cognitive recovery. Additionally, pharmacological interventions or brain stimulation could be valuable tools in supporting neuroplasticity and optimizing recovery.

A significant challenge remains the persistent fatigability many patients experience after surgery. While objective assessments often show normal cognitive function, patients frequently report feeling fatigued. This underscores the need for further research into the neural basis of post-surgical fatigue and the development of effective interventions to alleviate this debilitating symptom.

The Future of IDH-Mutated Glioma Treatment: Combining Neuroscience with New Therapies

Ng et al.’s study reinforces the importance of maximal resections in improving survival and functionality for IDH-mutated glioma patients. As we move forward, combining advances in neuroscience with targeted therapies like vorasidenib and innovations in brain stimulation will likely lead to even better outcomes. With ongoing research into neuroplasticity, tumor resection, and patient care, the future holds exciting possibilities for improving both the longevity and quality of life for patients diagnosed with IDH-mutated grade 2 gliomas.

Key Takeaways:

• Maximal resection, including supratotal resections, significantly improves survival in IDH-mutated grade 2 glioma patients.

• Extensive resection combined with awake neuropsychological monitoring preserves cognitive function and enhances long-term outcomes.

• The use of vorasidenib and new brain stimulation techniques may further optimize recovery and patient quality of life.

• Specialized care centers are essential for ensuring the best treatment outcomes for these rare and complex tumors.

By leveraging the latest advances in IDH-mutated glioma treatment, the prognosis for patients continues to improve, paving the way for better clinical outcomes and a higher quality of life.